Literature DB >> 14656882

Vdelta2-Jalpha rearrangements are frequent in precursor-B-acute lymphoblastic leukemia but rare in normal lymphoid cells.

Tomasz Szczepanski1, Vincent H J van der Velden, Patricia G Hoogeveen, Maaike de Bie, Daniëlle C H Jacobs, Elisabeth R van Wering, Jacques J M van Dongen.   

Abstract

The frequently occurring T-cell receptor delta (TCRD) deletions in precursor-B-acute lymphoblastic leukemia (precursor-B-ALL) are assumed to be mainly caused by Vdelta2-Jalpha rearrangements. We designed a multiplex polymerase chain reaction tified clonal Vdelta2-Jalpha rearrangements in 141 of 339 (41%) childhood and 8 of 22 (36%) adult precursor-B-ALL. A significant proportion (44%) of Vdelta2-Jalpha rearrangements in childhood precursor-B-ALL were oligoclonal. Sequence analysis showed preferential usage of the Jalpha29 gene segment in 54% of rearrangements. The remaining Vdelta2-Jalpha rearrangements used 26 other Jalpha segments, which included 2 additional clusters, one involving the most upstream Jalpha segments (ie, Jalpha48 to Jalpha61; 23%) and the second cluster located around the Jalpha9 gene segment (7%). Real-time quantitative PCR studies of normal lymphoid cells showed that Vdelta2 rearrangements to upstream Jalpha segments occurred at low levels in the thymus (10(-2) to 10(-3)) and were rare (generally below 10(-3)) in B-cell precursors and mature T cells. Vdelta2-Jalpha29 rearrangements were virtually absent in normal lymphoid cells. The monoclonal Vdelta2-Jalpha rearrangements in precursor-B-ALL may serve as patient-specific targets for detection of minimal residual disease, because they show high sensitivity (10(-4) or less in most cases) and good stability (88% of rearrangements preserved at relapse).

Entities:  

Mesh:

Year:  2003        PMID: 14656882     DOI: 10.1182/blood-2003-08-2952

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  13 in total

Review 1.  Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies.

Authors:  Jacques J M van Dongen; Vincent H J van der Velden; Monika Brüggemann; Alberto Orfao
Journal:  Blood       Date:  2015-05-21       Impact factor: 22.113

2.  Monitoring minimal residual disease in children with high-risk relapses of acute lymphoblastic leukemia: prognostic relevance of early and late assessment.

Authors:  C Eckert; N Hagedorn; L Sramkova; G Mann; R Panzer-Grümayer; C Peters; J-P Bourquin; T Klingebiel; A Borkhardt; G Cario; J Alten; G Escherich; K Astrahantseff; K Seeger; G Henze; A von Stackelberg
Journal:  Leukemia       Date:  2015-03-09       Impact factor: 11.528

3.  Clonal origins of ETV6-RUNX1⁺ acute lymphoblastic leukemia: studies in monozygotic twins.

Authors:  D Alpar; D Wren; L Ermini; M B Mansur; F W van Delft; C M Bateman; I Titley; L Kearney; T Szczepanski; D Gonzalez; A M Ford; N E Potter; M Greaves
Journal:  Leukemia       Date:  2014-11-12       Impact factor: 11.528

4.  Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia.

Authors:  Prisca Theunissen; Ester Mejstrikova; Lukasz Sedek; Alita J van der Sluijs-Gelling; Giuseppe Gaipa; Marius Bartels; Elaine Sobral da Costa; Michaela Kotrová; Michaela Novakova; Edwin Sonneveld; Chiara Buracchi; Paola Bonaccorso; Elen Oliveira; Jeroen G Te Marvelde; Tomasz Szczepanski; Ludovic Lhermitte; Ondrej Hrusak; Quentin Lecrevisse; Georgiana Emilia Grigore; Eva Froňková; Jan Trka; Monika Brüggemann; Alberto Orfao; Jacques J M van Dongen; Vincent H J van der Velden
Journal:  Blood       Date:  2016-11-30       Impact factor: 22.113

5.  Leukemia-associated genetic aberrations in mesenchymal stem cells of children with acute lymphoblastic leukemia.

Authors:  Shabnam Shalapour; Cornelia Eckert; Karl Seeger; Madlen Pfau; Javier Prada; Günter Henze; Thomas Blankenstein; Thomas Kammertoens
Journal:  J Mol Med (Berl)       Date:  2010-02-14       Impact factor: 4.599

Review 6.  Is Next-Generation Sequencing the way to go for Residual Disease Monitoring in Acute Lymphoblastic Leukemia?

Authors:  Michaela Kotrova; Jan Trka; Michael Kneba; Monika Brüggemann
Journal:  Mol Diagn Ther       Date:  2017-10       Impact factor: 4.074

7.  Determining the repertoire of IGH gene rearrangements to develop molecular markers for minimal residual disease in B-lineage acute lymphoblastic leukemia.

Authors:  Michael J Brisco; Sue Latham; Rosemary Sutton; Elizabeth Hughes; Vicki Wilczek; Katrina van Zanten; Bradley Budgen; Anita Y Bahar; Maria Malec; Pamela J Sykes; Bryone J Kuss; Keith Waters; Nicola C Venn; Jodie E Giles; Michelle Haber; Murray D Norris; Glenn M Marshall; Alexander A Morley
Journal:  J Mol Diagn       Date:  2009-03-26       Impact factor: 5.568

8.  Implementation of the standard strategy for identification of Ig/TCR targets for minimal residual disease diagnostics in B-cell precursor ALL pediatric patients: Polish experience.

Authors:  Małgorzata Dawidowska; Justyna Jółkowska; Tomasz Szczepański; Katarzyna Derwich; Jacek Wachowiak; Michał Witt
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2008-12-01       Impact factor: 4.291

Review 9.  Immune Gene Rearrangements: Unique Signatures for Tracing Physiological Lymphocytes and Leukemic Cells.

Authors:  Michaela Kotrova; Nikos Darzentas; Christiane Pott; Claudia D Baldus; Monika Brüggemann
Journal:  Genes (Basel)       Date:  2021-06-27       Impact factor: 4.096

10.  Extremely low-frequency magnetic fields and survival from childhood acute lymphoblastic leukemia: an international follow-up study.

Authors:  J Schüz; K Grell; S Kinsey; M S Linet; M P Link; G Mezei; B H Pollock; E Roman; Y Zhang; M L McBride; C Johansen; C Spix; J Hagihara; A M Saito; J Simpson; L L Robison; J D Dockerty; M Feychting; L Kheifets; K Frederiksen
Journal:  Blood Cancer J       Date:  2012-12-21       Impact factor: 11.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.